Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth”, 5351 [E6-1389]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 21 / Wednesday, February 1, 2006 / Notices
cchase on PROD1PC60 with NOTICES
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7848, Bethesda, MD 20892, 301–435–
2309, pluded@csr.nih.gov.
Name of Committee: Respiratory Sciences
Integrated Review Group, Lung Cellular,
Molecular, and Immunobiology Study
Section.
Date: February 22–23, 2006.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Wyndham City Center Hotel, 1143
New Hampshire Ave., NW., Washington, DC
20037.
Contact Person: George M. Barnas, PhD.,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2180,
MSC 7818, Bethesda, MD 20892, 301–435–
0696, barnasg@csr.nih.gov.
Name of Committee: Oncological Sciences
Integrated Review Group, Chemo/Dietary
Prevention Study Section.
Date: February 22–24, 2006.
Time: 5 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Latham Hotel, 3000 M Street, NW.,
Washington, DC 20007.
Contact Person: Sally A. Mulhern, PhD.,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6198,
MSC 7804, Bethesda, MD 20892, (301) 435–
5877, mulherns@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group, Neural Basis of Psychopathology,
Addictions and Sleep Disorders Study
Section.
Date: February 22–24, 2006.
Time: 6 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: Julius Cinque, MS.,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7846, Bethesda, MD 20892, (301) 435–
1252, cinquej@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS.)
Dated: January 24, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–919 Filed 1–31–06; 8:45 am]
BILLING CODE 4140–01–M
VerDate Aug<31>2005
17:49 Jan 31, 2006
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: ‘‘Vasostatin as Marrow
Protectant’’ and ‘‘Use of Calreticulin
and Calreticulin Fragments To Inhibit
Endothelial Cell Growth and
Angiogenesis and Suppress Tumor
Growth’’
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1) (i), announces that the
Department of Health and Human
Services is contemplating the grant of an
exclusive license to practice the
inventions embodied in U.S. Patent No.
6,596,690 B2 entitled ‘‘Vasostatin as
Marrow Protectant’’ (HHS Reference E–
230–2000/0); U.S. Patent Application
No. 09/807,148 filed April 5, 2001,
entitled ‘‘Use of Calreticulin and
Calreticulin Fragments To Inhibit
Endothelial Cell Growth and
Angiogenesis and Suppress Tumor
Growth’’ (HHS Reference E–082–1998/
0–US–03); PCT Application No. PCT/
US99/23240 filed October 5, 1999
entitled ‘‘Use of Calreticulin and
Calreticulin Fragments To Inhibit
Endothelial Cell Growth and
Angiogenesis and Suppress Tumor
Growth’’ (HHS Reference E–082–1998/
0–PCT–02); to RxKinetix, Inc. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to
development and sale of a
pharmaceutical product useful in
protecting bone marrow stem cells from
the toxic effects of chemotherapy and
radiotherapy.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before April 3, 2006 will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: Mojdeh
Bahar, J.D., Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804. Telephone:
(301) 435–2950; Facsimile: (301) 402–
0220; E-mail: baharm@od.nih.gov.
PO 00000
Frm 00120
Fmt 4703
Sfmt 4703
5351
The
technology claimed in the
aforementioned patents is based on the
discovery of the calreticulin N-domain
(vasostatin) and the three previously
uncharacterized properties of
calreticulin. First, calreticulin N-domain
is shown to stimulate the proliferation
and survival in vitro of hematopoietic
cells in the presence of previously
identified growth factors. Second,
Vasostatin is shown to protect
hematopoietic cells in vitro from
toxicity induced by a variety of
chemotherapeutic agents. Third,
Vasostatin is shown to protect a subject
from toxicity to the hematopoietic
system induced by chemotherapy or
irradiation.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
This is a modification to the notice
published in 70 FR 96, January 3, 2005.
SUPPLEMENTARY INFORMATION:
Dated: January 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–1389 Filed 1–31–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
[Docket No. DHS–2005–0057]
Software Assurance Program: Building
Better Quality and More Secure
Software
National Cyber Security
Division, DHS.
ACTION: Notice of availability.
AGENCY:
SUMMARY: The purpose of this notice is
to inform the public and interested
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 71, Number 21 (Wednesday, February 1, 2006)]
[Notices]
[Page 5351]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-1389]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive License: ``Vasostatin as Marrow
Protectant'' and ``Use of Calreticulin and Calreticulin Fragments To
Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor
Growth''
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1) (i), announces that the Department of Health and Human
Services is contemplating the grant of an exclusive license to practice
the inventions embodied in U.S. Patent No. 6,596,690 B2 entitled
``Vasostatin as Marrow Protectant'' (HHS Reference E-230-2000/0); U.S.
Patent Application No. 09/807,148 filed April 5, 2001, entitled ``Use
of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell
Growth and Angiogenesis and Suppress Tumor Growth'' (HHS Reference E-
082-1998/0-US-03); PCT Application No. PCT/US99/23240 filed October 5,
1999 entitled ``Use of Calreticulin and Calreticulin Fragments To
Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor
Growth'' (HHS Reference E-082-1998/0-PCT-02); to RxKinetix, Inc. The
patent rights in these inventions have been assigned to the United
States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to development and sale of a
pharmaceutical product useful in protecting bone marrow stem cells from
the toxic effects of chemotherapy and radiotherapy.
DATES: Only written comments and/or license applications which are
received by the National Institutes of Health on or before April 3,
2006 will be considered.
ADDRESSES: Requests for copies of the patent and/or patent
applications, inquiries, comments and other materials relating to the
contemplated exclusive license should be directed to: Mojdeh Bahar,
J.D., Technology Licensing Specialist, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804. Telephone: (301) 435-2950; Facsimile: (301)
402-0220; E-mail: baharm@od.nih.gov.
SUPPLEMENTARY INFORMATION: The technology claimed in the aforementioned
patents is based on the discovery of the calreticulin N-domain
(vasostatin) and the three previously uncharacterized properties of
calreticulin. First, calreticulin N-domain is shown to stimulate the
proliferation and survival in vitro of hematopoietic cells in the
presence of previously identified growth factors. Second, Vasostatin is
shown to protect hematopoietic cells in vitro from toxicity induced by
a variety of chemotherapeutic agents. Third, Vasostatin is shown to
protect a subject from toxicity to the hematopoietic system induced by
chemotherapy or irradiation.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establish that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
This is a modification to the notice published in 70 FR 96, January
3, 2005.
Dated: January 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-1389 Filed 1-31-06; 8:45 am]
BILLING CODE 4140-01-P
